NEWSROOM

BSEM

BioStem Announces Notice of Allowance for U.S. Patent Application for Sterile Human Placental Allografts

BioStem Announces Notice of Allowance for U.S. Patent Application for Sterile Human Placental Allografts

Nov 25, 2024

Company continues to advance its placental-derived product portfolio with the first patent granted in the fenestrated wound care market POMPANO BEACH, Fla., Nov. 25, 2024 - PRISM MediaWire - BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for...

BioStem Technologies Signs Letter of Intent to Acquire Wound Care Products and Technologies from ProgenaCare Global

BioStem Technologies Signs Letter of Intent to Acquire Wound Care Products and Technologies from ProgenaCare Global

Nov 20, 2024

Additions of ProgenaMatrix®and revyve™ Antimicrobial Wound Gel part of planned expansion of BioStem’s commercial product portfolio POMPANO BEACH, Fla., November 20, 2024 - PRISM MediaWire - BioStem Technologies Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacture, and commercialization of placental-derived biologics, today announced the signing of a Letter of Intent (LOI) to acquire commercial-stage products and development technologies from ProgenaCare Global...

BioStem Announces Notice of Allowance for U.S. Patent Application for Sterile Human Placental Allografts

BioStem Technologies Reports Record Third Quarter 2024 Revenue of $82.6 Million

Nov 12, 2024

Company reports third sequential quarter of record growth, contributing to a record total of $199.0 million in revenue for the first nine-months of 2024 Achieves third consecutive quarter of positive GAAP net income of $6.8 million or $0.42 per share. Generated Q3 2024 Adjusted EBITDA of $9.9 million Financial Results Conference Call and Webcast on Tuesday, November 12, 2024, at 4:30 pm ET POMPANO BEACH, FL, November 12, 2024 - PRISM MediaWire - BioStem Technologies, Inc. (OTC: BSEM) (the...

BioStem Technologies Initiates Nationwide Launch of Vendaje AC® with Venture Medical Following Established Reimbursement in All Medicare Administrative Contractor (MAC) Regions

BioStem Technologies Initiates Nationwide Launch of Vendaje AC® with Venture Medical Following Established Reimbursement in All Medicare Administrative Contractor (MAC) Regions

Oct 29, 2024

The pricing announcement from the Center for Medicare Services became effective on October 1, 2024, and allows BioStem to begin marketing initiatives with Venture Medical POMPANO BEACH, Fla., October 29, 2024 - PRISM MediaWire - BioStem Technologies Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacture, and commercialization of placental-derived biologics for advanced wound care, announces it will initiate a nationwide launch of Vendaje AC® with Venture Medical,...

BioStem Technologies Initiates Nationwide Launch of Vendaje AC® with Venture Medical Following Established Reimbursement in All Medicare Administrative Contractor (MAC) Regions

BioStem Technologies to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024

Oct 28, 2024

Conference Call and Webcast to be held at 4:30 PM ET POMPANO BEACH, Fla., October 28, 2024 - PRISM MediaWire - BioStem Technologies Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacture, and commercialization of placental-derived biologics for advanced wound care, announces that it will release its Third quarter 2024 financial results on Tuesday, November 12, 2024, and host a conference call and webcast at 4:30 PM ET to discuss the results. The webcast will...

BioStem Technologies Initiates Nationwide Launch of Vendaje AC® with Venture Medical Following Established Reimbursement in All Medicare Administrative Contractor (MAC) Regions

BioStem Technologies Reports Breakthrough Results in a Diabetic Foot Ulcer Wound Closure Study Comparing BioREtain® to Standard of Care Treatment

Oct 17, 2024

Retrospective Study demonstrates clinical efficacy and statistical support for tissue processed via BioREtain to care for treatment-resistant chronic wounds Study published in the peer-reviewed journal, ‘International Wound Journal’ POMPANO BEACH, Fla., Oct. 17, 2024 - PRISM MediaWire - BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived biologics for advanced wound care, announces breakthrough...

BioStem Technologies Initiates Nationwide Launch of Vendaje AC® with Venture Medical Following Established Reimbursement in All Medicare Administrative Contractor (MAC) Regions

BioStem Technologies Establishes National Pricing for Vendaje AC® from the Center for Medicare Services and Provides Reimbursement in All MAC Regions

Oct 15, 2024

Vendaje AC to launch across MAC regions nationwide through Venture Medical, the Company’s exclusive sales and marketing partner for AmnioWrap2® POMPANO BEACH, Fla., Oct. 15, 2024 - PRISM MediaWire - BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacture, and commercialization of placental-derived biologics for advanced wound care, today announced that the Center for Medicare Services (CMS) has established national pricing for its allograft...

BioStem Technologies Initiates Nationwide Launch of Vendaje AC® with Venture Medical Following Established Reimbursement in All Medicare Administrative Contractor (MAC) Regions

BioStem Technologies Initiates BR-AC-DFU-101 Clinical Trial to Study BioREtain® in Diabetic Foot Ulcers

Oct 2, 2024

Strategic head-to-head study of BR-AC vs. standard of care aims to demonstrate healing superiority potential to support increased payor coverage and market growth The study will be conducted in 60 patients at 10 sites across the U.S. and the first patients have begun treatment POMPANO BEACH, Florida, October 2, 2024 - BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacture, and commercialization of placental-derived biologics for advanced wound...

BioStem Technologies Initiates Nationwide Launch of Vendaje AC® with Venture Medical Following Established Reimbursement in All Medicare Administrative Contractor (MAC) Regions

BioStem Technologies, Inc. Files Form 10 with the Securities and Exchange Commission and Submits Nasdaq Application for Uplisting

Sep 30, 2024

Nasdaq listing aims to increase market visibility and global liquidity opportunities as BioStem advances its commercial and clinical initiatives amid record revenue growth Pompano Beach, FL, September 30, 2024 - PRISM MediaWire - BioStem Technologies, Inc. (OTC: BSEM) (“BioStem” or the “Company”), a leading MedTech company focused on the development, manufacture and commercialization of placental-derived biologics, announces the filing of a Form 10 registration statement (the “Registration...

BioStem Technologies Inc. to Present at the H.C. Wainwright 26th Annual Global Investment Conference in New York on September 9th at 3:30 PM ET

BioStem Technologies Inc. to Present at the H.C. Wainwright 26th Annual Global Investment Conference in New York on September 9th at 3:30 PM ET

Aug 29, 2024

Advanced wound care MedTech company recently reported a record second-quarter with $116.4M in revenue for H1, 2024 POMPANO BEACH, Fla., Aug. 29, 2024 -- BioStem Technologies Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacture, and commercialization of placental-derived biologics for advanced wound care, will present at the H.C. Wainwright 26th Annual Global Investment Conference held on September 9th through 11th in New York City at the Lotte Palace Hotel....

BioStem Technologies Inc. to Present at the H.C. Wainwright 26th Annual Global Investment Conference in New York on September 9th at 3:30 PM ET

BioStem Receives Institutional Review Board (IRB) Approval to Advance Clinical Study Evaluating the Value of Vendaje® Compared to the Standard of Care for Non-Healing Diabetic Foot Ulcers

Aug 21, 2024

Study supports BioStem’s strategic growth initiatives and accelerates product adoption by providing data to healthcare professionals and payers on the benefits of Vendaje POMPANO BEACH, FL, August 21, 2024 - BioStem Technologies Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacture, and commercialization of placental-derived biologics for advanced wound care, announces that the Institutional Review Board (IRB) has approved a clinical study to evaluate Vendaje® for...

BioStem Technologies Reports Record Second Quarter 2024 Revenue of $74.5 Million

BioStem Technologies Reports Record Second Quarter 2024 Revenue of $74.5 Million

Aug 12, 2024

Company reports transformative second-quarter revenue, contributing to a record total of $116.4 million in revenue for the first half of 2024 AmnioWrap2 continues to be a major growth driver achieving an impressive 56.5% sequential revenue increase compared to Q1 2024 Achieves second consecutive quarter of positive net income with $6.3 million Generated Adjusted Q2 2024 EBITDA of $10.0 million Financial Results Conference Call and Webcast on Monday, August 12, 2024, at 4:30 pm EDT POMPANO...

BioStem Technologies Reports Record Second Quarter 2024 Revenue of $74.5 Million

BioStem Technologies to Report Second Quarter 2024 Financial Results on Monday, August 12, 2024

Aug 5, 2024

Conference Call and Webcast to be held at 4:30 PM ET POMPANO BEACH, Fla., August 5, 2024, — BioStem Technologies, Inc. (OTC: BSEM), a leading medtech company specializing in the development, manufacture, and commercialization of placental-derived allografts for advanced wound care, announced today that it will release its second quarter 2024 financial results after the market close on Monday, August 12, 2024. The company will also host a conference call and webcast at 4:30 PM ET to discuss the...

BioStem Receives Institutional Review Board (IRB) Approval to Advance a Clinical Study Evaluating AmnioWrap2™ in Diabetic Foot Ulcers

BioStem Receives Institutional Review Board (IRB) Approval to Advance a Clinical Study Evaluating AmnioWrap2™ in Diabetic Foot Ulcers

Jul 10, 2024

POMPANO BEACH, FL, July 10, 2024 - BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental-derived biologics for advanced wound care, announces that the IRB has approved a clinical study to evaluate AmnioWrap2™ (AW2) in diabetic foot ulcers (DFU), one of the company’s placental-derived allograft commercial products. Jason Matuszewski, CEO of BioStem, commented: “Diabetic foot ulcers are a...

BioStem Technologies Reports Breakthrough Results with AmnioWrap2® in Retrospective Wound Care Study

BioStem Technologies Reports Breakthrough Results with AmnioWrap2® in Retrospective Wound Care Study

Jun 26, 2024

Study published in peer-reviewed journal finds BioStem’s products offer overall better treatment efficiency, and greater efficiency in general wound closure POMPANO BEACH, Fla., June 26, 2024 -- BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental derived allografts for advanced wound care, today announced that an article validating its proprietary processing method and its placental allograft...

BioStem Technologies Reports Breakthrough Results with AmnioWrap2® in Retrospective Wound Care Study

BioStem Technologies to Sponsor MRO Better Half Dash

May 29, 2024

POMPANO BEACH, Fla., May 29, 2024 - BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental-derived biologics, will sponsor the MRO Better Half Dash which will be held on May 29, 2024, from 4:00 PM – 9:00 PM at the Trackhouse Motorplex, 130 Motorplex Dr, Mooresville, NC. The Better Half Dash has become a beloved annual event in NASCAR, eagerly anticipated by fans and participants alike. Billy...

BioStem Technologies Reports Record First Quarter Revenue of $41.9 Million

BioStem Technologies Reports Record First Quarter Revenue of $41.9 Million

May 14, 2024

Company Achieves Record-Breaking First Quarter Results for 2024, Marking the Launch of BioStem 2.0 Company Reports First Quarter EBITDA of $4.9 Million Project Continued Growth from Sales of AmnioWrap2 ® Financial Results Conference Call and Webcast on Tuesday, May 14, 2024, at 4:30 pm EDT POMPANO BEACH, FLORIDA, May 14, 2024—BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental-derived...

BioStem Technologies Reports Record First Quarter Revenue of $41.9 Million

BioStem Technologies to Report First Quarter 2024 Financial Results on Tuesday, May 14, 2024

May 7, 2024

Conference Call on Tuesday, May 14th, at 4:30 pm ET POMPANO BEACH, FLORIDA, May 7, 2024—BioStem Technologies Inc. (OTC: BSEM), a leading biotechnology company focused on the development, manufacture, and commercialization of placental derived allografts for advanced wound care, announced today that it plans to release its first quarter 2024 financial results post-market on Tuesday, May 14, 2024. BioStem will host a conference call and webcast at 4:30 pm ET on Tuesday, May 14, 2024. The call...

BioStem Technologies Reports Record First Quarter Revenue of $41.9 Million

BioStem Technologies Granted Prioritized Examination for Wound Healing Patent

May 6, 2024

POMPANO BEACH, FLORIDA, May 6, 2024—BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental derived allografts for advanced wound care, today announced that the United States Patent and Trademark Office (USPTO) has granted the Company’s request for Prioritized Examination for its application for U.S. Patent 18/290,914 titled STERILE HUMAN PLACENTAL ALLOGRAFTS AND METHODS OF MAKING THEREOF. “As we...

BioStem Technologies Reports Record First Quarter Revenue of $41.9 Million

BioStem Technologies Retains Clinical Research Industry Veteran Nick McCoy to Lead DFU and VLU trials for BioREtain Allografts

Apr 30, 2024

POMPANO BEACH, FLORIDA, April 30, 2024—BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental-derived tissue allografts for advanced wound care, today announced that it has retained the services of Mr. Nick McCoy, who will lead BioStem’s Diabetic Foot Ulcer (DFU) and Venous Leg Ulcer (VLU) clinical trials process as a consultant to the Company. BioStem’s clinical focus on completing these...

BioStem Technologies Reports Record First Quarter Revenue of $41.9 Million

BioStem Technologies to Present at the 2024 Planet MicroCap Showcase

Apr 25, 2024

BioStem CEO, Jason Matuszewski, will present on Wednesday, May 1, 2024, at 11.30 am PST POMPANO BEACH, FLORIDA, April 25, 2024—BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental derived biologics for advanced wound care, today announced that it will present at the Planet MicroCap Showcase: VEGAS 2024 held at the Paris Hotel & Casino, in Las Vegas, NV., from April 30 - May 2 2024....

BioStem Technologies Reports Record First Quarter Revenue of $41.9 Million

BioStem Technologies Inc. Completes Two-Year Audit, Prepares for Uplisting to Senior Exchange

Apr 24, 2024

Strategic Audit Completion Set to Enhance BioStem Technologies' Market Position and Shareholder Value POMPANO BEACH, FLORIDA, April 24, 2024—BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental derived biologics, today announced the successful completion of comprehensive audits for fiscal years 2022 and 2023. This completion is a significant step in the company’s strategy to uplist to a...

BioStem Technologies Reports Record First Quarter Revenue of $41.9 Million

BioStem Technologies to Present at the 14th Annual LD Micro Invitational Conference

Apr 2, 2024

BioStem CEO, Jason Matuszewski, will present on Tuesday, April 9, 2024, at 12:30 pm ET POMPANO BEACH, FLORIDA, April 2, 2024—BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental-derived biologics for advanced wound care, today announced that it will present at the 14th Annual LD Micro Invitational Conference at the Sofitel New York on April 8-9, 2024. BioStem’s Chief Executive Officer, Jason...

BioStem Technologies Reports Record First Quarter Revenue of $41.9 Million

BioStem Technologies Reports Fourth Quarter Revenue of $11.5 Million, 14-Fold YoY Increase

Apr 1, 2024

-Project Continued Growth from Sales of AmnioWrap2®- -Financial Results Conference Call and Webcast on Monday, April 1, 2024 at 4:30 pm EDT- POMPANO BEACH, FLORIDA, April 1, 2024—BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental derived biologics, today reported financial results for the fourth quarter and twelve months ended December 31, 2023. Jason Matuszewski, CEO of BioStem,...

BioStem Technologies Reports Record First Quarter Revenue of $41.9 Million

BioStem Technologies to Report Fourth Quarter 2023 Financial Results on Monday, April 01, 2024

Mar 21, 2024

Conference Call on Monday, April 1st, at 4:30 pm ET POMPANO BEACH, FLORIDA, March 21, 2024 - BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental derived biologics for advanced wound care, announced today that it plans to release its fourth quarter 2023 financial results post-market Monday, April 01, 2024. BioStem will host a conference call and webcast at 4:30 pm ET on Monday, April 01, 2024....

PRISM MarketView Spotlights BioStem Technologies in the Expanding Wound Care Market

PRISM MarketView Spotlights BioStem Technologies in the Expanding Wound Care Market

Feb 26, 2024

New York, N.Y. February 26, 2024 - PRISM MarketView announces the release of an insightful interview with BioStem Technologies' (OTC: BSEM) CEO, Jason Matuszewski, discussing the company's strategic focus on revolutionizing the wound care market through innovative regenerative medicine solutions. BioStem Technologies, a frontrunner in regenerative medicine, is dedicated to leveraging the healing properties of placental-derived allografts to enhance wound care. The company stands out for its...

BioStem Technologies Reports Record First Quarter Revenue of $41.9 Million

Amniowrap2™ Product Launch Leads Year of Highlights for BioStem Technologies

Jan 30, 2024

BioStem provides a business update and highlights recent accomplishments Preliminary fourth quarter net revenues of $11.5 million and full year 2023 net revenues of $16.7 million National Pricing for Amniowrap2™ effective January 1st in all 50 states and territories POMPANO BEACH, FLORIDA, January 30, 2024 - BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental-derived allografts for advanced...

BioStem Technologies Reports Record First Quarter Revenue of $41.9 Million

BioStem Technologies Appoints Proven Life Science Sales Leader Shawn McCarrey to Chief Commercial Officer Role

Jan 11, 2024

Mr. McCarrey brings a strong track record of success and deep experience in regenerative medicine markets POMPANO BEACH, FLORIDA, January 11, 2024 - BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental-derived biologics for advanced wound care, today announces it has appointed a proven life science sales leader, Mr. Shawn McCarrey, as Chief Commercial Officer. BioStem Technologies CEO, Jason...

BioStem Technologies Appoints Executive Leader Patrick Daly to Board of Directors

BioStem Technologies Appoints Executive Leader Patrick Daly to Board of Directors

Dec 19, 2023

POMPANO BEACH, FLORIDA, December 19, 2023 - BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental-derived biologics for advanced wound care, today announces it has appointed Mr. Patrick Daly to its Board of Directors. Mr. Daly is an award-winning executive leader with a strong track record of success in operations, strategy, sales, marketing, fundraising, and partnership-building. BioStem...

Center for Medicare Services Established National Pricing of AmnioWrap2 (TM) in All MAC Regions

Dec 14, 2023

Pricing Provides AmnioWrap2TM Reimbursement in All MAC Regions POMPANO BEACH, FLORIDA, December 14, 2023 - BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental derived biologics for advanced wound care, announced that the Center for Medicare Services (CMS) has established national pricing for its product, AmnioWrap2TM, in all Medicare Administrative Contractors (MAC) regions. This pricing...